Axsome Therapeutics (NASDAQ:AXSM) Stock, Quote.Headers.trade-ideas

Axsome Therapeutics

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Biotech

Earnings

Earnings Beats

Mid Cap

News

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

AXSM

FULC

JAZZ

KRYS

Axsome Therapeutics, Inc. (NASDAQ: AXSM) announced that the FDA has accepted its resubmitted new drug application (NDA) seeking approval for AXS-07 for the acute treatment of migraine.

FDA Accepts AXSM&#39;s NDA Resubmission for Migraine Drug, Stock Up

ACAD

Axsome Therapeutics&#39; (NASDAQ: AXSM) first marketed drug, Auvelity (AXS-05), was launched in the United States in 2022 for the treatment of major depressive disorder, making it the first approved drug in the company&#39;s portfolio.

Axsome Banks on Auvelity &amp; Sunosi to Fuel Growth

Le ultime operazioni degli insider: cosa sta succedendo sui mercati?

Price Target

CRWD

EBAY

EVER

FRPT

PLTR

RXST

Lithia Motors To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday

Axsome Therapeutics Inc

Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Overweight and maintains $107 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $107 Price Target

Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $129.06, along with a high estimate of $180.00 and a low estimate of $95.00. Observing a 0.41% increase, the current average has risen from the previous average price target of $128.53. 
<img src="https://www.benzinga.com/files/images/story/2024/1725897676_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Axsome Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Cerena Chen</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$106.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$131.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Buy</td>
<td>$106.00</td>
<td>$106.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Axsome Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Axsome Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Axsome Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Axsome Therapeutics analyst ratings.</a>
<h2>Get to Know Axsome Therapeutics Better</h2>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>Axsome Therapeutics: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Axsome Therapeutics showcased positive performance, achieving a revenue growth rate of 86.65% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -91.03%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Axsome Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -64.28%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Axsome Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -14.51%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Axsome Therapeutics's debt-to-equity ratio is below the industry average at 1.86, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Axsome Therapeutics Stock

Axsome Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axsm#NASDAQ">AXSM</a>) announced that the FDA has accepted its resubmitted new drug application (NDA) seeking approval for AXS-07 for the acute treatment of migraine.
A final decision from the regulatory body is expected on Jan. 31, 2025. The FDA has designated the NDA resubmission as a Class 2 resubmission.
Shares of AXSM were up 6.6% on Sept. 4 following the announcement of the news.
Year to date, shares of Axsome have rallied 20.1% against the industry&#39;s decrease of 0.9%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/61/76711.jpg?v=1627352938" />
Image Source: Zacks Investment Research
The FDA issued a complete response letter to the first NDA for AXS-07 in April 2022 as it identified issues related to the chemistry, manufacturing and controls.
The NDA re-submission for AXS-07 for the acute treatment of migraine was completed during the second quarter of 2024. The FDA has not requested any additional safety or efficacy data for the NDA resubmission.
The NDA re-submission was earlier expected to be filed during the second half of 2023.
<h2>FDA Nod for AXS-07 to Diversify AXSM&#39;s Product Portfolio</h2>
Axsome currently has two marketed products in its commercial portfolio &ndash; Auvelity (AXS-05) for major depressive disorder and Sunosi (solriamfetol) for narcolepsy. A potential FDA nod for AXS-07 will diversify Axsome&#39;s commercial portfolio
Auvelity was launched in the United States in 2022 for the treatment of MDD, making it the first approved drug in the company&#39;s portfolio. The drug generated sales worth $118.4 million in the first half of 2024, up 172.8% year over year, owing to strong underlying demand.
Axsome&#39;s second marketed drug, Sunosi, is approved for treating narcolepsy. The company acquired U.S. rights to Sunosi from Jazz Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jazz#NASDAQ">JAZZ</a>) in May 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.
Jazz received approval for Sunosi as a treatment for narcolepsy in 2019.
The acquisition of Sunosi from Jazz diversified Axsome&#39;s portfolio to two marketed drugs. In the first half of 2024, Sunosi&#39;s net product sales were $42.2 million, reflecting an increase of almost 35.2% year over year.
<h2>Zacks Rank &amp; Stocks to Consider</h2>
Axsome currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 50.6%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 49.9%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 22.2%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2332290/fda-accepts-axsm-s-nda-resubmission-for-migraine-drug-stock-up?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2332290">To read this article on Zacks.com click here.</a>

FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $180 price target.

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target

Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $130 price target.

Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target

WIIM

Axsome Therapeutics shares are trading after the company announced the FDA has acknowledged a resubmission of its new drug application of AXS-07 for acute treatment of migraines.

The FDA designated the resubmission as a Class 2 resubmission and set a Prescription Drug User Fee Act (PDUFA) action goal date of January 31, 2025.

Axsome Therapeutics Says FDA Has Acknowledged Resubmission Of New Drug Application For AXS-07 For Acute Treatment Of Migraine

Wells Fargo analyst Cerena Chen initiates coverage on Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Overweight rating and announces Price Target of $140.

Initiation

Wells Fargo Initiates Coverage On Axsome Therapeutics with Overweight Rating, Announces Price Target of $140

Across the recent three months, 14 analysts have shared their insights on Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Axsome Therapeutics, presenting an average target of $132.14, a high estimate of $190.00, and a low estimate of $95.00. A decline of 0.18% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1724335211_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Axsome Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$106.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$131.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Buy</td>
<td>$106.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$127.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Axsome Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Axsome Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Axsome Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Axsome Therapeutics analyst ratings.</a>
<h2>Delving into Axsome Therapeutics's Background</h2>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>A Deep Dive into Axsome Therapeutics's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Axsome Therapeutics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 86.65%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Axsome Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -91.03%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Axsome Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -64.28%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Axsome Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -14.51%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Axsome Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 1.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 14 Analyst Insights On Axsome Therapeutics

Legal

Axsome Therapeutics Reaches Agreement With Sandoz To Dismiss Sunosi Patent Litigation

Axsome Therapeutics&#39; (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axsm#NASDAQ">AXSM</a>) first marketed drug, Auvelity (AXS-05), was launched in the United States in 2022 for the treatment of major depressive disorder, making it the first approved drug in the company&#39;s portfolio.
The drug generated sales worth $118.4 million in the first half of 2024, up 172.8% year over year, owing to strong underlying demand. The momentum is likely to continue for the remainder of 2024.
Axsome is also conducting several label expansion studies on Auvelity targeting other central nervous system&nbsp;disorders like Alzheimer&#39;s disease (AD) associated agitation and smoking cessation.
Currently, two separate phase III studies are evaluating Auvelity for treating agitation associated with AD. Top-line data from both studies are expected later in the second half of 2024.
AXSM is planning to initiate a phase II/III pivotal study on AXS-05 for smoking cessation later in 2024.
The successful development and subsequent commercialization of Auvelity in additional indications will help the drug address a broader patient population and drive sales further.
Axsome acquired U.S. rights to Sunosi, a commercialized drug targeting narcolepsy, from Jazz Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jazz#NASDAQ">JAZZ</a>) in May 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.
Jazz received approval for Sunosi as a treatment for narcolepsy in 2019.
The acquisition of Sunosi from Jazz diversified Axsome&#39;s portfolio to two marketed drugs. In the first half of 2024, Sunosi&#39;s net product sales were $42.2 million, reflecting an increase of almost 35.2% year over year. Sunosi has become an important revenue driver for Axsome.
In February 2023, AXSM entered into a licensing agreement with Pharmanovia to market Sunosi in Europe and certain Middle East/North African countries. Axsome receives royalties on Sunosi sales in out-licensed territories.
Axsome has an impressive portfolio of pipeline candidates, including AXS-07, AXS-12 and AXS-14. All of these are being developed for various CNS indications.
AXS-07 is being developed for the acute treatment of migraine. After several delays, the company resubmitted its NDA for AXS-07 to the FDA for the acute treatment of migraine in the second quarter of 2024. A decision from the regulatory body is expected within six months.
Though Axsome is riding on the success of Auvelity and Sunosi, competition looms large on the company in the target market as many companies are developing treatments to address various CNS disorders. One such company is Acadia Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acad#NASDAQ">ACAD</a>), which is currently developing Nuplazid (pimavanserin) in several studies targeting different CNS indications.
ACAD&#39;s Nuplazid is already approved for hallucinations and delusions associated with Parkinson&#39;s disease psychosis.
Acadia is also studying pimavanserin for the treatment of other CNS disorders.
<a href="https://www.zacks.com/stock/news/2322688/axsome-axsm-banks-on-auvelity-sunosi-to-fuel-growth?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2322688">To read this article on Zacks.com click here.</a>

Axsome Banks on Auvelity & Sunosi to Fuel Growth

UBS analyst Ashwani Verma maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and lowers the price target from $107 to $105.

UBS Maintains Buy on Axsome Therapeutics, Lowers Price Target to $105

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler cut the price target for CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) from $310 to $290. Piper Sandler analyst Rob Owens upgraded the stock from Neutral to Overweight. CrowdStrike shares gained 1.9% to close at $222.05 on Monday. <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank raised the price target for Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) from $20 to $21. Deutsche Bank analyst Brad Zelnick maintained the stock with a Sell rating. Palantir shares fell 2.6% to close at $24.09 on Monday. <a href="https://www.benzinga.com/quote/PLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) price target from $75 to $54. Needham analyst David Saxon maintained a Buy rating. RxSight shares fell 2.4% to close at $40.78 on Monday. <a href="https://www.benzinga.com/quote/RXST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised the price target for Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) from $95 to $106. B of A Securities analyst Jason Gerberry upgraded the stock from Neutral to Buy. Axsome Therapeutics shares fell 1.4% to close at $83.21 on Monday. <a href="https://www.benzinga.com/quote/AXSM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised Freshpet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) price target from $135 to $140. Baird analyst Peter Benedict maintained an Outperform rating. Freshpet shares fell 0.6% to close at $121.41 on Monday. <a href="https://www.benzinga.com/quote/FRPT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised Lithia Motors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) price target from $280 to $315. JP Morgan analyst Rajat Gupta maintained an Overweight rating. Lithia Motors shares fell 4.6% to close at $276.76 on Monday. <a href="https://www.benzinga.com/quote/LAD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised the price target for EverQuote, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) from $30 to $38. Needham analyst Mayank Tandon maintained a Buy rating. EverQuote shares fell 3.5% to close at $23.96 on Monday. <a href="https://www.benzinga.com/quote/EVER/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital boosted Tyson Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) price target from $58 to $60. BMO Capital analyst Andrew Strelzik maintained a Market Perform rating. Tyson shares rose 2.1% to close at $62.51 on Monday. <a href="https://www.benzinga.com/quote/TSN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities raised eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) price target from $50 to $58. Truist Securities analyst Youssef Squali maintained a Hold rating. EVgo shares fell 2.7% to close at $54.66 on Monday. <a href="https://www.benzinga.com/quote/EBAY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised AutoNation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) price target from $155 to $160. JP Morgan analyst Rajat Gupta maintained a Neutral rating. AutoNation shares dipped 2.7% to close at $166.06 on Monday. <a href="https://www.benzinga.com/quote/AN/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40178833/dow-records-worst-day-in-around-2-years-mag-7-stocks-lose-650b-in-market-capitalization-greed-index">Dow Records Worst Day In Around 2 Years, Mag 7 Stocks Lose $650B In Market Capitalization: Greed Index Moves To &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and lowers the price target from $131 to $130.

RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $130

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and lowers the price target from $190 to $180.

HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Lowers Price Target to $180

B of A Securities analyst Jason Gerberry upgrades Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) from Neutral to Buy and raises the price target from $95 to $106.

Upgrades

B of A Securities Upgrades Axsome Therapeutics to Buy, Raises Price Target to $106

The Prognosis For ProKidney: Unclear

Morgan Stanley analyst Vikram Purohit has maintained their bullish stance on AXSM stock, giving a Buy rating on August 22. Vikram Purohit has given...

Strong Buy Rating for Axsome as Auvelity Sales Surge and Growth Potential Solidifies

Axsome migraine therapy undergoes FDA review again

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $180....

Buy Rating Affirmed for Axsome Therapeutics on Robust Pipeline and Promising Regulatory Prospects

Needham analyst Ami Fadia maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $130.00. Ami Fadi...

Buy Rating Affirmed for Axsome Therapeutics on Strong Pipeline and Promising Drug Trials

In a report released on September 4, Charles Duncan from Cantor Fitzgerald maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report),...

Axsome Therapeutics (AXSM) Gets a Buy from Cantor Fitzgerald

Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) yesterday and set a price target of $...

Strong Market Penetration and Commercial Success of Axsome's Auvelity Justifies Buy Rating

TD Cowen analyst Joseph Thome maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $120.00. The ...

TD Cowen Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

RBC Capital analyst Leonid Timashev maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $130.00...

RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of $11...

Axsome Therapeutics: A Strong Buy on Auvelity's Robust Market Performance and Growth Prospects

NTLA

PROK

Screenshot 2024-07-10 at 9.08.28 PM

TNXP

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-02-24 at 12.03.42 AM

ABBV

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Press Releases

Axsome Therapeutics Supports Alzheimer's & Brain Awareness Month

Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5

Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

Axsome Therapeutics to Participate in Investor Conferences in September

Health Care

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Axsome Therapeutics

Axsome Therapeutics (AXSM) Forecast

Axsome Therapeutics (NASDAQ:AXSM) Stock, Quote.Headers.trade-ideas